Matthew Barcus Stock Analyst Profile - Chardan Capital Research Coverage - Stocknear

Matthew Barcus

Stock Analyst at Chardan Capital

(3.7)
# 2314
Out of 5,506 analysts
36
Total ratings
Success rate
Average return
Main Sectors:
Top Industries:

12 Stocks

Name Action PT Current % Upside Ratings Updated
ZURA Zura Bio
Maintains: Buy
12 10
3.93 154.45% 3 Mar 26, 2025
QURE uniQure
Maintains: Buy
45 27
54.92 -50.84% 4 Jun 22, 2023
XLO Xilio Therapeutics
Reiterates: Buy
7
0.82 753.66% 3 May 30, 2023
IMVT Immunovant
Maintains: Strong Buy
21 32
16.9 89.35% 4 May 23, 2023
PPBT Purple Biotech
Reiterates: Buy
220
0.59 37188.14% 3 May 17, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
144 126
n/a n/a 3 May 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
9
3.27 175.23% 3 Apr 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 3 Mar 28, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
9 8
12.38 -35.38% 1 Mar 17, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Dec 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
80 60
n/a n/a 3 Nov 17, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 4 Jul 21, 2022